81021-97-8Relevant articles and documents
CHDI-626, a PET Tracer Candidate for Imaging Mutant Huntingtin Aggregates with Reduced Binding to AD Pathological Proteins
Bard, Jonathan A.,Brown, Christopher J.,Chen, Xuemei,Clark-Frew, Daniel,Coe, Samuel,Conlon, Mike,Davis, Randall,Dominguez, Celia,Ensor, Samantha,Esposito, Simone,Gai, Xinjie,Green, Samantha,Greenaway, Catherine,Haber, James,Halldin, Christer,Hayes, Sarah,He?mann, Manuela,Herbst, Todd,Herrmann, Frank,Hsai, Ming Min,Johnson, Peter D.,Khetarpal, Vinod,Kotey, Adrian,Lee, Matthew R.,Liu, Longbin,Mangette, John E.,Mills, Matthew R.,Monteagudo, Edith,Moren, Anton Forsberg,Mrzljak, Ladislav,Munoz-Sanjuan, Ignacio,Nag, Sangram,Nibbio, Martina,Orsatti, Laura,Prime, Michael E.,Schaertl, Sabine,Scheich, Christoph,Sproston, Joanne,Stepanov, Vladimir,Varn?s, Katarina,Varrone, Andrea,Wityak, John
supporting information, p. 12003 - 12021 (2021/09/02)
The expanded polyglutamine-containing mutant huntingtin (mHTT) protein is implicated in neuronal degeneration of medium spiny neurons in Huntington's disease (HD) for which multiple therapeutic approaches are currently being evaluated to eliminate or redu
PROBES FOR IMAGING HUNTINGTIN PROTEIN
-
Paragraph 0435; 0436, (2017/03/21)
Provided are imaging agents comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and methods of their use.
IMIDAZO[2,1-B]THIAZOLE AND 5,6-DIHYDROIMIDAZO[2,1-B]THIAZOLE DERIVATIVES USEFUL AS S100-INHIBITORS
-
Page/Page column 116; 121, (2016/04/09)
A compound of formula (I) or a pharmaceutically acceptable salt thereof. The compound is useful for use in the treatment of cancer, an inflammatory disorder,an autoimmunity disorder or a neurodegenerative disorder.
